This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • Phase III SEER-1 trial of RGN 259 shows efficacy i...
News

Phase III SEER-1 trial of RGN 259 shows efficacy in neurotrophic keratopathy.- ReGenTree + RegeneRx Biopharma

Read time: 1 mins
Last updated:18th May 2020
Published:16th May 2020
Condition: Neurotrophic Keratopathy
Type: drug
Register now for full access to medthority.com